Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Eli Lilly And Co (LLY) Price & Performance

Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Alcon AG vs Eli Lilly And Co — how do they compare? Alcon AG trades at $73.32 (market cap $36.44B), while Eli Lilly And Co trades at $1,222.8 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 29.6× Alcon AG's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.

ALCLLY
Market Cap
$36.44B$1.08T
Sector
HealthHealth
52-Week High
$90.12$1.24K
52-Week Low
$62.02$639.43
Enterprise Value
$40.28B$1.13T
Dividend Yield
0.48%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alcon AG

ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.

The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY